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Estimates for South Africa for 2010 were that approximately 5.6 
million people were HIV-infected,1 accounting for the largest 
number of cases in a single country.2 According to the latest South 
African National Antenatal Survey (2010), 30.2% of pregnant 
women in South Africa were HIV-positive,3 maternal mortality 
was 6 times higher among HIV-positive women, and more than 
half of all maternal deaths were attributable to HIV.4 About 40 000 
children in South Africa are infected with HIV each year, with HIV/
AIDS a major contributor to infant mortality in South Africa.5 But 
amidst the bad news has been some good: more than 1.56 million 
people in South Africa are now receiving ART, and the introduction 
of more robust and better-tolerated antiretrovirals (ARVs) such 
as tenofovir disoproxil fumarate (TDF) for first-line therapy is 
narrowing the gap between recommended treatment protocols in 
rich and poor countries. In addition, exciting new knowledge and 
evidence about the concept of ‘treatment as prevention’ (TasP) has 
emerged, showing not only the therapeutic but also the potential 
preventive benefits of ART. Prevention of mother-to-child 
transmission (PMTCT) as TasP is not new – but it currently lags 
behind other programme goals and ART scale-up efforts.6 Earlier 
initiation of treatment for pregnant women provides extra benefits 
in PMTCT. While efavirenz (EFV) has been recommended in the WHO 
guidelines for initiation of eligible women after the first trimester; 
its use in pregnant women has been restricted in the South African 
Clinical PMTCT guidelines, where all pregnant women are initiated 
on a nevirapine (NVP)-based regimen.7 In consequence, as South 
Africa seeks ways in which new knowledge can be integrated 
into existing programmes that could have measurable effects on 
mortality and morbidity,8 this review presents the latest evidence 
of safety and efficacy of EFV in pregnancy.
Is there really an optIon for women?
To date, limited and complicated PMTCT and treatment options exist 
for women infected with HIV. The latest WHO PMTCT guidelines 
offer lifelong ART for those with CD4<350 cells/mm3 and allow 
resource-limited settings two options for those with CD4 >350 
cells/mm³: A or B.9 Option B offers all women triple therapy for 
the duration of pregnancy until the cessation of breast feeding for 
those with CD4>350 cells/mm3. The view that option B is superior 
to option A is emerging, for several reasons:10
its simplicity for women and programmes, as option A is 
especially complicated and requires many regimen changes6
option B allows more women to have sustained exposure to 
HAART. For those who may fall pregnant during breastfeeding, 
HAART allows women to survive longer,11 which is important for 
survival of their children.
option B may have an added preventative benefit for pregnant 
women’s partners in discordant relationships12
the unknown risk of non-nucleoside reverse transcriptase 
inhibitor (NNRTI) resistance in the mother or infant, despite 
prophylaxis13
safety, effectiveness and feasibility of daily infant NVP beyond 
6 months of age; and maternal and infant acceptability of daily 
infant prophylaxis for a long period as well as acceptability in 
programme settings is largely unknown
option B may be better for women, with a growing consensus 
demonstrating that there are individual benefits for the mother 
as well as for public health.10
Option B, although simpler, has some drawback for women who fall 
pregnant again or become eligible for lifelong ART, as they would 
need to restart HAART. This essentially translates into treatment 
interruption. Some countries, such as Malawi, have elaborated 
on option B. Malawi is now implementing what is termed ‘Option 
B+’, which is lifelong ART for all pregnant women, irrespective of 
CD4 cell count, from 14 weeks’ gestation. To achieve this, Malawi 
has included EFV as part of a fixed-dose once-daily formulation 
for treatment of pregnant women. This decision was justified on 
the basis that the limited potential risk of birth defects owing to 
efavirenz is far outweighed by the increased public health benefit, 
coverage, and reduced overall mortality of initiating mothers on 
HAART.14
Is efavIrenz safe to use In pregnanc y?
Efavirenz’s FDA rating was changed from category C to category D 
in 2005, based on data from animal studies and retrospective case 
reports of neural tube defects.15 Evidence of teratogenicity linked 
The WHO recommends starting lifelong ART for all pregnant women with a CD4 count at or below 350 cells/mm³, which recognises 
the important component of ‘when to start’ and the role that timing of initiation plays in reducing mortality and disease progres-
sion. The data on ‘what to start’ are conflicting, and options for resource-limited settings are limited. The choice of an ART regimen 
for pregnant women is complicated by the need to take into account the health and safety of both the mother and baby. Particularly 
contentious is whether to use a nevirapine- (NVP) or efavirenz- (EFV) based regimen. This review presents the latest evidence on the 
safety and efficacy of EFV and NVP in pregnancy and offers recommendations for improving maternal and child health outcomes and 
avoid mother-to-child transmission as South Africa moves toward turning back the tide on its HIV epidemic.
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to the use of EFV in pregnancy has been limited since then, and 
current evidence suggests that the risk is lower than previously 
thought.16,17
Current WHO guidelines recommend avoiding EFV in the first 
trimester only, but also note that overall rates of birth defects in 
infants exposed to EFV, NVP and TDF are similar to those in the 
general population.9 It is evident that the risk of birth defects on 
exposure to any of the widely used antiretroviral agents shows 
a similar risk (NVP 2.5%, EFV 2.7% and AZT 3.3%) (Table 2). In 
addition, the risks are similar for first, second and third trimester 
exposures (Table 3). In review of the data till 31 January 2011, 
among the prospective Antiretroviral Pregnancy Registry (APR) 
reports, the prevalence of birth defects per 100 live births among 
women with a first trimester exposure to any of the antiretroviral 
therapies included in the APR is 2.9% (95% confidence interval 
(CI) 2.5 - 3.4) i.e. 164 outcomes with defects of 5 555 live births.18 
The prevalence of defects is not significantly different from the 
prevalence of defects among women with an initial exposure 
during the second and/or third trimester of 2.7% (prevalence 
ratio 1.08, 95% CI 0.88 - 1.32)/205 birth defects in 7 483 live 
births.18 The APR result for EFV exposure in the first trimester is 
2.7% (95% CI 1.6 - 4.3), and 2.9% (95% CI 0.3 - 10) for second- 
and third-trimester exposure to EFV. The most recent updated 
meta-analysis as at July 2011 (which reviews the APR and other 
prospective cohorts) showed a pooled prevalence of 2% (95% CI 
0.82 - 3.18) and relative risk of birth defects in EFV-containing ART 
regimens to non-EFV-based ART as 0.85 (95% CI 0.61 - 1.20).17 This 
confirms no increased risk of overall birth defects among women 
receiving first-trimester efavirenz. Comparatively, the risks in 
the general population are also quite similar (Table 3): in the 
USA, the prevalence of birth defects in the general population is 
approximately 3% of live births; and in South Africa the prevalence 
is estimated at 5.3%.19
However, concerns have been raised, owing to retrospective 
reports of myelo-meningocoeles received after the FDA category 
change. The risk of neural tube abnormalities exists before it closes 
by 28 days. The prevalence of neural tube defects (NTD) globally is 
0.1 - 0.4%, while in South Africa it is estimated at 0.23 - 0.36%.19 
taBle 1. arv prophylaXIs optIons recommenDeD for hIv-InfecteD pregnant women who Do not neeD treatment 
for theIr own health
option a: maternal azt option B: maternal triple arv prophylaxis 
mother mother
•	 Antepartum AZT (from as early as 14 weeks’ gestation)
•	 sd-NVP at onset of labour*
•	 AZT + 3TC during labour and delivery*
•	 AZT + 3TC for 7 days postpartum*
*sd-NVP and AZT+3TC can be omitted if mother receives >4 weeks of AZT 
antepartum 
Triple ARV from 14 weeks until one week after all exposure to breast milk 
has ended
•	 AZT + 3TC + LPV/r 
•	 AZT + 3TC + ABC 
•	 AZT + 3TC + EFV 
•	 TDF + 3TC (or FTC) + EFV 
Infant Infant
Breastfeeding infant
Sd-NVP at birth plus daily NVP from birth until one week after all exposure 
to breast milk has ended
non-breastfeeding infant
Sd-NVP at birth plus AZT or NVP from birth until 4 - 6 weeks
Breastfeeding infant
AZT or NVP from birth until 4 - 6 weeks
non-breastfeeding infant 
AZT or NVP from birth until 4 - 6 weeks
Source: WHO Rapid Advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, November 2009. Revised June 2010.
taBle 2. comparatIve rates of BIrth Defects for wIDely useD arvs In the fIrst trImester
first trimester exposure arv Defects/live births prevalence (95% cI)
Indinavir 6/285 2.1% (0.8% - 4.5%)
Lopinavir 16/738 2.2% (1.2% - 3.5%)
Atazanavir sulfate 12/502 2.4% (1.2% - 4.1%)
Stavudine 19/797 2.4% (1.4% - 3.7%)
Ritonavir 33/1401 2.4% (1.6% - 3.3%)
Tenofovir 26/1092 2.4% (1.6% - 3.5%)
Nevirapine 25/987 2.5% (1.6% - 3.7%)
Emtricitabine 17/641 2.7% (1.5% - 4.2%)
Efavirenz 17/623 2.7% (1.6% - 4.3%)
Abacavir 22/744 3.0% (1.9% - 4.5%)
Lamivudine 118/3864 3.1% (2.5% - 3.7%)
Zidovudine 118/3620 3.3% (2.7% - 3.9%)
Nelfinavir 46/1193 3.9% (2.8% - 5.1%)
Didanosine 19/406 4.7% (2.8% - 7.2%)
Source: Antiretroviral Pregnancy Register (APR) Interim report 201118
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The recent 2011 meta-analysis shows the incidence of neural tube 
defects (until July 2011) to be low, at 0.07 (95% CI 0.002 - 0.39).17 
Given the low baseline prevalence of neural tube defects, many 
more first-trimester efavirenz exposures would be required to 
quantify the risk. Potentially, it would take a long time for a South 
African (or another country’s) registry to accumulate sufficient 
data to allow firmer conclusions to be drawn. In addition, a 
major problem of retrospective reports is the reporting bias. 
Retrospective reports can be biased toward the reporting of more 
unusual and severe cases, and are less likely to be representative 
of the general population experience. Therefore, the calculation of 
prevalence from these reports is often inappropriate and needs to 
be interpreted with caution.
To summarise: current data on efavirenz use in pregnancy shows 
little and poorly supported evidence of risk to the fetus, with a 
non-significant relative risk of only 0.85 (95% CI 0.61 - 1.20) with 
EFV, compared with non-EFV-based exposure in the first trimester. 
There is no significant increase in risk of NTDs with EFV exposure.
Importantly, as for any ARV drug, it is not possible to conclusively 
say that EFV is safe, and drug companies and regulatory bodies are 
therefore unlikely to change the  EFV rating out of fear of litigation. 
Noteworthy is the difference between category X and category D 
(Table 4); and the latter allows policy decision-makers, clinicians 
and patients alike to weigh up the evidence and allow judgment 
in their best interests. The FDA is currently proposing to update its 
approach to labeling.20
consequences on comprehensIve seXual 
reproDuctIve health
Another potentially harmful consequence of the EFV category D 
rating is reported in data on termination of pregnancy (TOP) for 
women exposed to efavirenz-containing and non-efavirenz-
containing regimens. These reveal a RR of 2.81 (95% CI 0.94 - 
8.36) for efavirenz-exposed women.17 These TOPs are not informed 
by prenatal screening and could mean that women on EFV are 
almost 3 times more likely to have a potentially distressing and 
unnecessary TOP based on the potential risk of teratogenicity and 
not the actual presence of a birth defect. This has far-reaching 
harmful consequences for the woman and for clinicians who 
could be inadvertently ill-advising patients on the basis of poorly 
supported evidence of risk.
Recent studies in Johannesburg show that issues around providers 
and information transferred to patients about efavirenz risk in 
pregnancy are often misunderstood. In one study, 40.7% of 851 
women declared that the healthcare provider had not discussed 
pregnancy options with them. A small proportion (6.4%) said a 
provider had told them not to have more children, and 36% were 
unsure whether their provider had approved of them having 
children.21 Furthermore, women on both EFV and NVP had similar 
taBle 4. fDa categorIes of rIsk
category Description
A controlled studies show no risk
Adequate, well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester of pregnancy.
B no evidence of risk in humans
Adequate, well-controlled studies in pregnant women have not shown increased risk of fetal abnormalities despite adverse findings in 
animals  
or 
In the absence of adequate human studies, animal studies show no fetal risk. The chance of fetal harm is remote, but remains a possibility.
C risk cannot be ruled out
Adequate, well-controlled human studies are lacking, and animal studies have shown a risk to the fetus, or are lacking as well. 
There is a chance of foetal harm if the drug is administered during pregnancy, but the potential benefits may outweigh the potential risk.
D positive evidence of risk
Studies in humans, or investigational or post-marketing data, have demonstrated foetal risk. Nevertheless, potential benefits from the use 
of the drug may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious 
disease for which safer drugs cannot be used or are ineffective.
X contra-indicated in pregnancy
Studies in animals or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or 
risk which clearly outweighs any possible benefit to the patient.
Source: FDA20
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3% 5.3% 2.9% 2.7% 2.7% 2.9% 2.0%
95% cI: (2.5 - 3.4) (0.88 - 1.32) (1.6 - 4.3) (0.3 - 10.0) (0.82 - 3.18)
numbers: 164/5 555 205/7 483 17/643 2/70 39/1 437
Relative risk 1st trimester EFV to non-EFV ART was 0.85 (0.61 - 1.20)17
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pregnancy intentions – either trying to conceive or planning to do 
so.21 Pettifor and Rees found in 2005 that roughly 33% of women 
planned their pregnancies.22 Complexity of personal reproductive 
health issues for women and their relationship with healthcare 
providers must be acknowledged.
what Do we know aBout the alternatIve – 
nevIrapIne?
Current WHO guidelines affirm the role of ARVs for pregnant 
women, and recommend the use of ARVs in differing combinations, 
depending on CD4 cell count, in all pregnant HIV-infected women. 
Consequently, according to current South African guidelines, many 
more women will be initiated on NVP-based regimens. Today, NVP 
is the recommended alternative to EFV in women of childbearing 
age.
The 2NN study23 (the largest randomised controlled trial (RCT), 
with more than 1 200 patients) found no difference in efficacy 
between NVP and EFV, and a systematic review of 7 RCTS24 also 
found no difference at 48 weeks. The authors recognise, however, 
that 48 weeks of follow-up is shorter than other cohort studies, 
which shows that the difference between EFV and NVP grows 
larger over time.23 When the Parkland cohort study data were 
censored at week 48 (using the endpoint in 2NN), there were no 
significant differences in time to virological failure (EFV = 38.9 
weeks v. NVP = 37.2 weeks, p = 0.20); however, when the patient 
cohort data were not censored at 48 weeks, significant differences 
were seen between EFV and NVP at 192 weeks (p<0.001).25,26 EFV 
was specifically found to provide a significantly longer time to 
treatment failure than NVP (EFV = 132 weeks v. NVP = 94.1 weeks, 
p = 0.027).25,26 Additionally, in the 2NN study, fewer patients 
taking EFV than those taking NVP experienced treatment failure 
(37.8% v. 47.3%).23
These results underscore the need to observe patients for 
longer periods of time to determine the extended durability of 
antiretroviral regimens. Since clinical trials are often difficult 
and expensive to maintain, observational cohort analyses may 
be an alternative for examining long-term durability. Many 
observational cohorts show that EFV is superior, with an increased 
risk of virological failure on NVP-based ART regimens.27-30 In June 
2011, at the IAS conference, a meta-analysis comparing TDF-
containing regimens raised concerns that TDF/3TC/NVP might have 
decreased virological efficacy compared with the EFV-containing 
TDF regimens.31 Therefore, we should be concerned about initiating 
women or switching them to a NVP-based regimen that might not 
necessarily be superior because of our poorly supported evidence 
of teratogenicity.
To date, there is conflicting evidence of severe adverse events 
(rash and hepatotoxicity) in pregnant women who have higher 
CD4 cell counts, initiating HAART with a NVP-containing regimen. 
In 2004, Boehringer-Ingelheim, manufacturers of NVP (Viramune) 
performed a retrospective analysis of hepatoxicity events 
and found no consistent CD4 cell-count cut-off that could be 
identified in women, that was associated with an increased risk 
of liver enzyme elevations. The analysis also demonstrated no 
significant differences in the rate of serious hepatic events among 
ARV regimens, including between the non-nucleoside reverse 
transcriptase inhibitors NVP and EFV.32 Further scrutiny of this 
analysis revealed that patients with symptomatic events were not 
included in the subset analysis. It also revealed the risk of rash-
associated hepatic adverse events was 3 times higher in women 
than in men. A rash-associated hepatic event was also associated 
with a higher CD4 cell count, with women with pre-treatment CD4 
count >250 cells/mm3 having a higher risk of hepatotoxicity than 
women with CD4 <250 cells/mm³.33 Following these results, the 
company changed the Summary of Product Characteristics to include 
a caution that women with higher CD4 cell counts are at increased 
risk of hepatic toxicity.34
Previously, it was not recommended to initiate women on 
NVP if their CD4 cell count was above 250 cells/mm³.35-37 Data 
are now emerging from both high-income38,39 and resource-
limited settings,32 suggesting that it is safe for patients who 
have experienced good increases in their CD4 cell counts on 
anotherARV regimen to switch to NVP (provided they have an 
undetectable viral load), even when their CD4 count is above the 
level recommended for initiating treatment. In 2009, Ouyang 
and colleagues showed that NVP is not uniquely associated with 
hepatoxicity in pregnancy but rather that pregnancy itself may 
be an independent risk factor.40 The same study also showed 
that NVP is not associated with hepatoxicity at higher CD4 cell 
counts. Chu et al.41 found in 2010 no association of CD4 cell count 
and hepatotoxicity; however, the median CD4 cell count in their 
cohort was low (112 cells/mm3) and, with resource-limited 
settings still pervaded by patients presenting late and initiated 
at low CD4 cell counts, this study highlights one of the possible 
reasons for the lack of observed difference between high-income 
and resource-limited settings.
Indeed, a Cambodian cohort study in a resource limited setting 
found (i) that higher CD4 cell counts at the time of NVP substitution 
from EFV increased the risk of subsequent NVP toxicity, and (ii) that 
ART-experienced Cambodians appear to have a risk of NVP toxicity 
comparable with that of ART-naive patients, despite higher CD4 
counts.42 The analysis from the large randomised clinical trial, the 
2NN study, demonstrated that the rate of skin rash and hepatic 
events was higher in patients with CD4 counts >200 cells/ml, 
and also that women with CD4 counts >200 cells/mm3 had a 
significantly greater risk of developing a rash than men.23,24 The 
most recent data from Uganda presented at the IAS conference in 
June 2011 have documented 3 cases of Stevens-Johnson syndrome 
in stable experienced HAART patients when switched to NVP.43 
Overall, the meta-analysis of 7 randomised controlled trials (RCTs) 
show that EFV had a lower incidence of adverse events (AEs) and 
fewer discontinuations than NVP.24 Fewer patients taking EFV 
discontinued therapy because of any AE or HIV event than patients 
taking the other treatment regimens. Two deaths were directly 
associated with NVP use (one from toxic hepatitis and the other 
from Stevens-Johnson syndrome); no deaths were associated with 
EFV. Overall, EFV was associated with a more favorable tolerability 
profile than NVP, with less grade 3 or 4 clinical AEs, fewer 
discontinuations for AEs, and numerically less treatment changes 
with EFV than with NVP.23
There therefore seems to be insufficient evidence to recommend 
that it is safe to switch NVP for EFV, in particular in settings such as 
South Africa with higher co-infection rates of TB i.e. women who 
are switched to and fro.44 It is possible that the WHO concluded 
that using NVP outweighs the risk of not initiating ART precisely 
because of the lack of an alternative for resource-limited settings. 
This is why EFV in pregnancy needs to be carefully rethought 
in light of the most recent evidence. The more toxic and life-
threatening alternative to EFV that puts a woman at increased risk 
needs to be urgently revisited.
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Is efavIrenz afforDaBle anD cost-effectIve?
The prohibitively high cost of EFV had prevented its widespread 
use in the early part of the decade, and the price evolution is 
demonstrative (Fig. 1). The Medicins Sans Frontieres (MSF) report 
Untangling the Web reveals that the cost of EFV has been driven 
down from the originator price of $347 in December 2002 to a 
WHO-prequalified generic price of $52 in July 2011 (per patient 
per year).45 Despite cost, perhaps more important is a recent study 
looking to quantify the benefit (life expectancy gains) and risk, 
that shows that the use of non-efavirenz-based initial ART in HIV-
infected women of childbearing age may reduce life expectancy 
gains from ART.46 The mean life expectancy for women who would 
start ART at a CD4<250 on NVP-based HAART was 25.49, compared 
with 27.08 for EFV-based ART, with a resultant 1.6-year life 
expectancy gain on EFV compared with NVP.46 In addition, survival 
of women who received an EFV-based ART regimen was 0.89 
years greater than all non-EFV-based regimens.46 Policymakers 
do indeed need to take into account cost and cost-effectiveness, 
but the benefit to women and their families favours EFV-based 
ART when reduced survival and potential life-threatening severe 
adverse events on NVP are quite stark. Today, the fixed-dose 
combination of tenofovir, lamivudine and efavirenz in a once-a-
day pill is likely to have positive spill-over effects for those women 
who need to take treatment every day for the rest of their lives, 
without jeopardising their own health and further resistance 
through poor adherence. 
conclusIons anD recommenDatIons
The above describes the most recent evidence available; could 
we expect more robust evidence? Randomised controlled trials 
(RCTs) (gold standard) are not feasible, and it would take a 
very long time to truly assess and compare outcomes. Modeling 
exercises can help to inform some potential future outlook for 
those questions not answered by available evidence today 
or when RCTs are not feasible. Ouattara et al.’s (2012) latest 
projections found that starting ART with EFV, which has a lower 
rate of switching owing to its toxicity profile, provides a benefit 
over NVP in survival at 10 years i.e. more women alive; and 
comparatively the rate of birth defects with EFV would need to 
be 2.3 times the rate of NVP to balance out the number of deaths 
of women on NVP.47 This seems unlikely if to date the APR birth 
defect rate for NVP is 2.7%, for EFV 2.9%, and the recent meta-
analysis by Ford et al. (2011) is 2.0%.
Therefore, the risk-benefit question for women is: Does the risk 
of birth defects (knowing that we have low and poorly supported 
risk to the fetus and enough data to say we don’t have a tenfold 
increase in risk of NTDs) after the organogenesis period on EFV 
outweigh the risks of life-threatening toxicity, regimen changes 
and a potential risk of failure when switching women from EFV to 
NVP? Particularly as South Africa has moved to earlier initiation of 
HAART at CD4<350 cells/mm³, many more women will be picked 
up early at antenatal clinic with the risk of severe adverse events 
being potentially higher in women with higher CD4 counts if 
switched to NVP.
It is important to bear in mind that most studies are confounded by 
HIV disease stage, smoking, co-morbidities and other medication. 
Generally, an HIV-infected population is possibly at increased risk 
of adverse outcomes of pregnancy unrelated to teratology, and in 
South Africa there is an extra burden of fetal alcohol syndrome. 
‘Fetal alcohol spectrum disorder is the most common birth defect 
in South Africa, by far more common than Down syndrome and 
neural-tube defects combined,’ according to Professor Denis 
Viljoen of the Foundation for Alcohol Related Research (FARR).48
Based on the evidence, there are several policy recommendations 
that the South African government should consider at this critical 
juncture while heading towards the ‘getting to zero’ goal.
Firstly, it should allow for already on HAART who fall pregnant 
to continue on EFV-based HAART instead of switching to NVP. 
Most pregnancies are not detected until at least one month 
after conception; switching to NVP after this point may not 
protect against birth defects, and needs to be balanced against 
the risk of serious adverse events caused by switching to NVP.
Secondly, it could allow only women who are on ART and who 
want to conceive to switch from EFV to NVP before falling 
pregnant.
All women of child-bearing age should be encouraged to plan 
their pregnancies and be tested before conception.
The South African government should consider moving to 
embrace Option B as preferred PMTCT, and to initiate all women 
in need of HAART them on the superior combination of TDF/3TC/
EFV from 14 weeks’ gestation. This has an added benefit of 
simplification for nurse-initiated ART as it is consistent with 
adult preferred first-line treatment; and has the potential to 
simplify the supply chain, thereby preventing potential stock-
outs.
Consider pilot projects that could ascertain the benefits and 
risks for individuals and at the population level, as well as 
programmatic implications for putting all pregnant women on 
HAART (Option B+).
Regulatory bodies and the government should fast-track 
the registration of the fixed-dose once-daily formulation of 
TDF/3TC/EFV for all patients.
Lastly, increased pharmaco-vigilance and a South Africa-wide 
prospective Antiretroviral Pregnancy Registry are needed. With 
the number of women exposed to EFV in the first trimester, 
however, it would take a very long time for a South African 
registry to accumulate enough data to allow firmer conclusions 
to be drawn; therefore, this should not be done at the expense 
of women in need of treatment now.
This paper has argued that, although we could never claim any 
ARV to be completely safe, weak associations in some studies 
are far outweighed by the benefits of HAART in pregnancy. The 
consideration to use EFV in the first trimester of pregnancy in 
resource-limited settings such as South Africa needs to move 
beyond concerns of poorly supported evidence to recognising new 
evidence of survival gains, efficacy, toxicity, direct medical and 
programmatic costs (including costs of simplification and scaling 
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up coverage) – as well as indirect costs e.g. unnecessary and 
distressing termination of pregnancies. This allows policymakers 
an opportunity to harness the evidence accumulated to date and 
focus on pursuing an effective strategy based on evidence and 
balancing risks and benefit of best prevention and treatment 
options for women and their families.
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